The publisher, together with the authors and editors, has taken great pains to ensure that all information presented in this work (programs, applications, amounts, dosages, etc.) reflects the standard of knowledge at the time of publication. Despite careful manuscript preparation and proof correction, errors can nevertheless occur. Authors, editors and publisher disclaim all responsibility for any errors or omissions of liability for the results obtained from use of the information, or parts thereof, contained in this work.

The citation of registered names, trade names, trademarks, etc. in this work does not imply, even in the absence of a specific statement, that such names are exempt from laws and regulations protecting trademarks etc. and therefore free for general use.

ISSN 0939-5075 · e-ISSN 1865-7125

All information regarding notes for contributors, subscriptions, Open access, back volumes and orders is available online at www.degruyter.com/journals/znc.

RESPONSIBLE EDITOR Prof. Dr. Juergen Seibel, Universitaet Wuerzburg, Institut fuer Organische Chemie, Am Hubland, 97074 Wuerzburg, Germany

PUBLISHER Walter de Gruyter GmbH, Berlin/Boston, Genthiner Straße 13, 10785 Berlin, Germany

JOURNAL EDITOR Ulrike Kitzing, De Gruyter, Genthiner Straße 13, 10785 Berlin, Germany. Tel.: +49 (0)30 260 05-344, e-mail: ulrike.kitzing@degruyter.com

RESPONSIBLE FOR ADVERTISEMENTS Markus Kügel, De Gruyter, Rosenheimer Str. 143, 81671 München, Germany. Tel.: +49 89 76 902-424, e-mail: anzeigen@degruyter.com

© 2022 Walter de Gruyter GmbH, Berlin/Boston, Germany

TYPESetting TNQ Technologies, Chennai, India

PRINTING Franz X. Stückle Druck und Verlag e. K., Ettenheim

COVER ILLUSTRATION Detail of the structure of bryostatin 1. The structure of bryostatin 1 was determined in 1982. To date 20 different bryostatins have been isolated. Bryostatins are potent modulators of protein kinase C. They are currently under investigation as anti-cancer agents, as anti-AIDS/HIV agents and as a memory-enhancing agent.
Contents

Research Articles

Bassam Oudh Aljohny, Yasir Anwar and Shahid Ali Khan
*In vitro* anticancer and antibacterial potentials of selected medicinal plants and isolation and characterization of a natural compound from *Withania coagulans* — 263

Mohamed Shaaban
*New compounds from Sarcophyton glaucom-derived Penicillium sp.* — 271

Zafer Sahin, Yağmur Özhan, Hande Sipahi, Sevde Nur Biltekin, Leyla Yurttas, Barkin Berk and Şeref Demirayak
*Novel benzofurane-pyrazole derivatives with anti-inflammatory, cyclooxygenase inhibitory and cytotoxicity evaluation* — 279

Jung Hwan Oh, Gi Baeg Nam, Fatih Karadeniz, Chang-Suk Kong and Jaeyoung Ko
*Evaluation and enzyme-aided enhancement of anti-photoaging properties of Camellia japonica in UVA-irradiated keratinocytes* — 287

Javier Hoyo, Arnau Bassegoda and Tzanko Tzanov
*Electrochemical quantification of biomarker myeloperoxidase* — 297

Lucia Dwi Antika, Aprilia Nur Tasfiyati, Hikmat Hikmat and Abdi Wira Septama
*Scopoletin: a review of its source, biosynthesis, methods of extraction, and pharmacological activities* — 303

Yasuo Kato and Taiji Nomura
*Occurrence of Z-2-oxo-4-methyl-3-pentene-1,5-dioic acid and its regioisomer 4-methylene-2-oxo-glutaric acid in tulip tissues* — 317

Fatemeh Yousefbeyk, Ghazaleh Hemmati, Ziba Gholipour, Saeed Ghasemi, Mehdi Evazalipour, Clara Schubert, Diba E. Koohi and Volker Böhm
*Phytochemical analysis, antioxidant, cytotoxic, and antimicrobial activities of golden chamomile (Matricaria aurea (Loefl.) Schultz Bip)* — 331

Tunay Karan, Ramazan Erenler and Busra Moran Bozer
*Synthesis and characterization of silver nanoparticles using curcumin: cytotoxic, apoptotic, and necrotic effects on various cell lines* — 343

Review Article

Abhijita Talukder, Chayanika Kalita, Nayanika Neog, Chayanika Goswami, Mrinal Kashyap Sarma and Iswar Hazarika
*A comparative analysis on the safety and efficacy of Covaxin versus other vaccines against COVID-19: a review* — 351

Corrigendum

Ruchika Mittal, Gauri Srivastava and Deepak Ganjewala
*Corrigendum to: an update on the progress of microbial biotransformation of commercial monoterpenes* — 363